WE GRATEFULLY THANK ALL OF OUR
2016 BIENNIAL MEETING SPONSORS
Astellas Pharma US, Inc., located in Northbrook, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas markets products in the areas of Anti-Infectives, Cardiology, Oncology, Transplant, and Urology. For more information about Astellas Pharma US, Inc., please visit our website at www.astellas.com.
Gilead Sciences, a research-based biopharmaceutical company, discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s therapeutic areas of focus include HIV/AIDS, liver diseases, haematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions. Gilead has a rapidly expanding product portfolio, a growing pipeline of investigational drugs, and over 8,000 employees in offices across six continents. Millions of people around the world are living healthier lives because of therapies developed by Gilead. www.gilead.com
For 125 years, Merck has been a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook, YouTube and LinkedIn www.merck.com
SCYNEXIS is a pharmaceutical company committed to develop and commercialize novel treatments to address significant unmet medical needs. Its lead candidate, SCY-078, an antifungal agent in Phase 2 clinical development, represents a new chemical class of glucan synthase inhibitors, available in both IV and oral formulations. SCY-078 has potent activity against Candida spp. and Aspergillus spp., including most azoles- and echinocandin-resistant strains. Intended indications include: invasive candidiasis, invasive aspergillosis and vulvovaginal candidiasis.
SCY-078 holds both Fast Track and Qualified Infections Disease Product (QIDP) designations for invasive candidiasis (including candidemia) and invasive aspergillosis. www.scynexis.com
Viamet discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. We also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. Focusing on the needs of patients and clinicians, we design our drug candidates to achieve superior efficacy and safety profiles compared to currently marketed drugs. www.viamet.com
Cidara is a clinical stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives. Our pipeline includes: CD101 IV, a novel long-acting high exposure echinocandin antifungal being developed for the treatment and prevention of serious invasive infections; CD101 topical, the first application of an echinocandin to a topical indication, in development for VVC and recurrent VVC; and candidates generated by our Cloudbreak™ immunotherapy platform, broadly applicable for the development of antifungals, antibacterials and antivirals. Cidara is based in San Diego, CA. www.cidara.com
For more than 35 years, IMMY has focused its attention on manufacturing high-quality diagnostics for fungal diseases. With products for cryptococcus, histoplasma, coccidioides, aspergillus, candida, and blastomyces, IMMY is setting the standard with accurate and affordable diagnostics. Our goal is to develop tests that give clear results, which direct diagnosis, and bridge the gap between patients and the proper treatment they need...Saving Lives One Diagnostic at a Time. www.immy.com
Matinas BioPharma, Inc. is a clinical-stage biopharmaceutical company transforming the way medicines are delivered and administered in order to provide patients with better tolerated and more powerful treatments in the battle against infectious diseases. Using our proprietary, lipid-crystal, nanoparticle technology, Matinas is able to provide three critical benefits: (1) oral administration of medicines which today are only able to be delivered intravenously, (2) multi-organ protection from otherwise highly toxic compounds, (3) targeted delivery to site of infection, with the potential to achieve rapid tissue penetration, days ahead of what is available with injected drugs. www.matinasbiopharma.com
Stop waiting days for blood culture results! T2 Biosystems offers the first and ONLY species-specific sepsis pathogen diagnostic panel -- requiring no blood culture -- delivering faster, easier and more accurate results in an average of 4.3 hours. Run on the fully-automated T2Dx® Instrument utilizing T2 Magnetic Resonance (T2MR®) technology, the T2Candida® Panel identifies the five clinically relevant species of Candida directly from whole blood which enables physician to initiate appropriate therapy on day zero. The T2Dx Instrument and the T2Candida Panel are FDA cleared and in use in over 30 hospitals worldwide. T2 Biosystems, Now You Know NOW. For more information, visit www.t2biosystems.com
MiraVista Diagnostics is a CAP and CLIA accredited mycology reference laboratory with an exclusive focus on developing and processing diagnostic tests for serious fungal infections. We offer the highest standards in accuracy and sensitivity for detection and monitoring of Blastomyces dermatitidis, Histoplasma capsulatum, Cryptococcus, Coccidioides, Aspergillus and (1–3)-β-D glucan. MiraVista Diagnostics was founded in 2002 and serves the medical community in the U.S. and Canada. We offer same-day testing, superior sensitivity and specificity and direct access to the laboratory’s team of experienced infectious disease specialists. MiraVista serves reference laboratories, hospitals, healthcare systems and university medical centers. For more information, please visit www.miravistalabs.com or call 317-455-2153.